← All candidates
One insider buy in the last year — $42.8K in all.
58 filings on record.
DYNDyne Therapeutics, Inc.
NasdaqGS · Healthcare · $3.23B
$17.31
-3.32% · Sep 16
One insider buy in the last year — $42.8K in all.
Nothing in the last fortnight.
Price · 1Y · daily● 1 buy● 40 sells◆ 5 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$3.23B
Float
186.2M
100% public
Short % float
Pro
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
CEO & President
Cox John
Bought $911.0K on Jul 14 — 100,000 sh @ $9.11, held direct, 41% of their stake.
1 of 1 position beat the S&P
Director
Posner Brian S
Bought $42.8K on May 20 — 2,500 sh @ $17.12, held direct, 14% of their stake.
0 of 1 position beat the S&P
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
2 filingsnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
53 more transactions on Pro →Context
Wall St
$37.20 avg target
+115.0% vs today · 15 analysts · consensus Strong Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
3 of 4 quarters beat
Q2 '26−$1.08 act−$0.33
Q1 '26−$0.73 act+$0.05
Q4 '25−$0.73 act+$0.03
Q3 '25−$0.76 act+$0.09
Coverage
Wall Street Weighs Impact On DYN Stock Post Novartis’ Phase 3 Failure — RBC Says These Key Differences Could Lead To Better OutcomesStocktwits · 1w agoDyne Therapeutics Myotonic Dystrophy Approach Remains Differentiated, RBC SaysMT Newswires · 1w agoDyne Therapeutics Shares Fall 31% Premarket With No Catalyst ConfirmedInvestorsHub · 1w agoDyne Therapeutics (DYN) Prices Upsized Share Offering, Is The Valuation Still Compelling?Simply Wall St. · 07-23
The file stays open
58 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice